nach oben

Erschienen in:

08.10.2021 | Review

Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations

verfasst von: Nikoletta Mili, Stavroula A. Paschou, Dimitrios G. Goulis, Meletios-Athanasios Dimopoulos, Irene Lambrinoudaki, Theodora Psaltopoulou

Erschienen in: Endocrine | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Overweight, obesity, and metabolic syndrome (MetS) have become epidemic conditions affecting 39%, 13%, and 20% of the population respectively. The aim of this article is to review the literature on the association of obesity and MetS with the risk of cancer. We also explore the effect of lifestyle modifications, such as diet, physical activity, and antidiabetic medications, on cancer incidence. Increased body mass index (BMI) has been associated with a multitude of site-specific cancers, reaching relative risk (RR) 1.54 [95% confidence interval (CI) 1.47–1.61] per 5 unit increase for endometrial cancer, as well as with overall cancer risk (RR 1.03, 95% CI 1.02–1.05). Central adiposity measured by waist circumference or waist-to-hip ratio has been suggested as a stronger predictor than BMI for several cancers, such as colorectal cancer. Metabolic Syndrome has been consistently and positively associated with the risk of very common cancers like colorectal (RR 1.34, 95% CI 1.24–1.44), endometrial (RR 1.62, 95% CI 1.26–2.07) and postmenopausal breast cancer (RR 2.01, 95% CI 1.55–2.60). Hyperglycemia and subsequently T2DM have been also shown to increase the risk of cancer. Nevertheless, these risk factors are modifiable and therefore implementing lifestyle modifications could prevent an important number of cancer cases. Adherence to cancer prevention guidelines, including maintaining a healthy weight, having regular physical exercise (RR 0.58–0.90 for different cite specific cancers) and following a healthy dietary pattern (RR 0.74–0.94 for different cite specific cancers) have a protective effect on the risk of cancer. The strength of this review is the presentation of the best evidence, as the data derive mainly from meta-analyses. Public health policies should focus on the modification of risk factors and future research is needed to reveal the pathophysiological links between these risk factors and cancer to develop more efficient prevention and treatment strategies.

Nur mit Berechtigung zugänglich

WHO. Obesity and overweight. (2016). https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Geneva. Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation. (2011). www.who.int. Accessed 2021

A.M. Barberio, A. Alareeki, B. Viner et al. Central body fatness is a stronger predictor of cancer risk than overall body size. Nat. Commun. 10,(2019). https://doi.org/10.1038/s41467-018-08159-w

B. Balkau, M.A. Charles, Comment on the provisional report from the WHO consultation. Diabet. Med. 16(5), 442–443 (1999). https://doi.org/10.1046/j.1464-5491.1999.00059.xCrossRefPubMed

J.I. Cleeman, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). J. Am. Med Assoc. 285(19), 2486–2497 (2001). https://doi.org/10.1001/jama.285.19.2486CrossRef

K.G.M.M. Alberti, P. Zimmet, J. Shaw, The metabolic syndrome—a new worldwide definition. Lancet 366(9491), 1059–1062 (2005). https://doi.org/10.1016/S0140-6736(05)67402-8CrossRefPubMed

K.G.M.M. Alberti, R.H. Eckel, S.M. Grundy et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; And international association for the study of obesity. Circulation 120(16), 1640–1645 (2009). https://doi.org/10.1161/CIRCULATIONAHA.109.192644CrossRefPubMed

S.M. Grundy, J.I. Cleeman, S.R. Daniels et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112(17), 2735–2752 (2005). https://doi.org/10.1161/CIRCULATIONAHA.105.169404CrossRefPubMed

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health Organization. (1999) https://apps.who.int/iris/handle/10665/66040

10.

E.S. Ford, Prevalence of the metabolic syndrome in US populations. Endocrinol. Metab. Clin. North Am. 33(2), 333–350 (2004). https://doi.org/10.1016/j.ecl.2004.03.004CrossRefPubMed

11.

P. Ranasinghe, Y. Mathangasinghe, R. Jayawardena, A.P. Hills, A. Misra A. Prevalence and trends of metabolic syndrome among adults in the Asia-pacific region: a systematic review. BMC Public Health. 17, (2017). https://doi.org/10.1186/s12889-017-4041-1

12.

A. Ansarimoghaddam, H.A. Adineh, I. Zareban, S. Iranpour, A. HosseinZadeh, F. Kh, Prevalence of metabolic syndrome in Middle-East countries: meta-analysis of cross-sectional studies. Diabetes Metab. Syndr. Clin. Res Rev. 12(2), 195–201 (2018). https://doi.org/10.1016/j.dsx.2017.11.004CrossRef

13.

A.L. Gutiérrez-Solis, S. Datta Banik, R.M. Méndez-González, Prevalence of metabolic syndrome in mexico: a systematic review and meta-analysis. Metab. Syndr. Relat. Disord. 16(8), 395–405 (2018). https://doi.org/10.1089/met.2017.0157CrossRefPubMed

14.

E.S. Ford, W.H. Giles, W.H. Dietz, Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey. J. Am. Med Assoc. 287(3), 356–359 (2002). https://doi.org/10.1001/jama.287.3.356CrossRef

15.

H. Beltrán-Sánchez, M.O. Harhay, M.M. Harhay, S. McElligott, Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999-2010. J. Am. Coll. Cardiol. 62(8), 697–703 (2013). https://doi.org/10.1016/j.jacc.2013.05.064CrossRefPubMedPubMedCentral

16.

W.G. Gao, Q. Qiao, J. Tuomilehto et al. Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J. Obes. 32(5), 757–762 (2008). https://doi.org/10.1038/sj.ijo.0803797CrossRef

17.

P.W.F. Wilson, J.B. Meigs, Cardiometabolic risk: a Framingham perspective. Int J. Obes. 32, S17–S20 (2008). https://doi.org/10.1038/ijo.2008.30CrossRef

18.

N. Sattar, A. McConnachie, A.G. Shaper et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371(9628), 1927–1935 (2008). https://doi.org/10.1016/S0140-6736(08)60602-9CrossRefPubMed

19.

P.W.F. Wilson, R.B. D’Agostino, H. Parise, L. Sullivan, J.B. Meigs, Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112(20), 3066–3072 (2005). https://doi.org/10.1161/CIRCULATIONAHA.105.539528CrossRefPubMed

20.

E.S. Ford, M.B. Schulze, T. Pischon, M.M. Bergmann, H.G. Joost, H. Boeing, Metabolic syndrome and risk of incident diabetes: Findings from the European prospective investigation into cancer and nutrition-potsdam study. Cardiovasc. Diabetol. 7, (2008). https://doi.org/10.1186/1475-2840-7-35

21.

E.S. Ford, C. Li, N. Sattar, Metabolic syndrome and incident diabetes. Diabetes Care 31(9), 1898–1904 (2008). https://doi.org/10.2337/dc08-0423CrossRefPubMedPubMedCentral

22.

S. Mottillo, K.B. Filion, J. Genest et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 56(14), 1113–1132 (2010). https://doi.org/10.1016/j.jacc.2010.05.034CrossRefPubMed

23.

A. Vryonidou, S.A. Paschou, G. Muscogiuri, F. Orio, D.G. Goulis, MECHANISMS IN ENDOCRINOLOGY: Metabolic syndrome through the female life cycle. Eur. J. Endocrinol. 173(5), R153–R163 (2015). https://doi.org/10.1530/EJE-15-0275CrossRefPubMed

24.

F.M. Mendonça, F.R. De Sousa, A.L. Barbosa et al. Metabolic syndrome and risk of cancer: which link? Metabolism 64(2), 182–189 (2015). https://doi.org/10.1016/j.metabol.2014.10.008CrossRefPubMed

25.

K. Esposito, P. Chiodini, A. Colao, A. Lenzi, D. Giugliano, Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 35(11), 2402–2411 (2012). https://doi.org/10.2337/dc12-0336CrossRefPubMedPubMedCentral

26.

M. Arnold, N. Pandeya, G. Byrnes et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16(1), 36–46 (2015). https://doi.org/10.1016/S1470-2045(14)71123-4CrossRefPubMed

27.

A.G. Renehan, M. Tyson, M. Egger, R.F. Heller, M. Zwahlen, Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612), 569–578 (2008). https://doi.org/10.1016/S0140-6736(08)60269-XCrossRefPubMed

28.

X. Fang, J. Wei, X. He et al. Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies. Int J. Cancer 143(7), 1595–1603 (2018). https://doi.org/10.1002/ijc.31553CrossRefPubMed

29.

A. Harikrishna, A. Ishak, A. Ellinides et al. The impact of obesity and insulin resistance on thyroid cancer: a systematic review. Maturitas 125, 45–49 (2019). https://doi.org/10.1016/J.MATURITAS.2019.03.022CrossRefPubMed

30.

G.I. Sydney, K.J. Ioakim, S.A. Paschou, Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas 121, 1–6 (2019). https://doi.org/10.1016/J.MATURITAS.2018.12.002CrossRefPubMed

31.

O. Raglan, I. Kalliala, G. Markozannes et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J. Cancer 145(7), 1719–1730 (2019). https://doi.org/10.1002/ijc.31961CrossRefPubMed

32.

I. Kalliala, G. Markozannes, M.J. Gunter et al. Obesity and gynaecological and obstetric conditions: umbrella review of the literature. BMJ 359, j4511 (2017). https://doi.org/10.1136/bmj.j4511CrossRefPubMedPubMedCentral

33.

World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report. Diet, nutrition, physical activity and endometrial cancer. (2018). Available at http://dietandcancerreport.org.

34.

B. Lauby-Secretan, C. Scoccianti, D. Loomis, Y. Grosse, F. Bianchini, K. Straif, Body Fatness and Cancer—viewpoint of the IARC Working Group. N. Engl. J. Med. 375(8), 794–798 (2016). https://doi.org/10.1056/nejmsr1606602CrossRefPubMedPubMedCentral

35.

D. Aune, D.A. Navarro Rosenblatt, D.S.M. Chan et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose-response meta-analysis of prospective studies. Ann. Oncol. 26(8), 1635–1648 (2015). https://doi.org/10.1093/annonc/mdv142CrossRefPubMed

36.

M.R. Wise, V. Jordan, A. Lagas et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: A systematic review. Am. J. Obstet. Gynecol. 214(6), 689.e1–689.e17 (2016). https://doi.org/10.1016/j.ajog.2016.01.175CrossRef

37.

A. Morra, A.Y. Jung, S. Behrens et al. Breast cancer risk factors and survival by tumor subtype: pooled analyses from the Breast Cancer Association Consortium. Cancer Epidemiol. Biomarkers Prev. (2021). https://doi.org/10.1158/1055-9965.epi-20-0924

38.

M. Kyrgiou, I. Kalliala, G. Markozannes et al. Adiposity and cancer at major anatomical sites: Umbrella review of the literature. BMJ. 356, (2017). https://doi.org/10.1136/bmj.j477

39.

C.J. Bull, J.A. Bell, N. Murphy et al. Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. BMC Med. 18, (2020). https://doi.org/10.1186/s12916-020-01855-9

40.

L. Abar, A.R. Vieira, D. Aune et al. Height and body fatness and colorectal cancer risk: an update of the WCRF–AICR systematic review of published prospective studies. Eur. J. Nutr. 57(5), 1701–1720 (2018). https://doi.org/10.1007/s00394-017-1557-1CrossRefPubMed

41.

P.A. Brandt, R.G. van den, Ziegler, M. Wang et al. Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: a pooled analysis of 20 prospective cohort studies. Eur. J. Epidemiol. 36(1), 37 (2021). https://doi.org/10.1007/S10654-020-00688-3CrossRefPubMed

42.

D.S.M. Chan, L. Abar, M. Cariolou et al. World cancer research fund international: continuous update project—systematic literature review and meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control 30(11), 1183–1200 (2019). https://doi.org/10.1007/s10552-019-01223-wCrossRefPubMed

43.

NM. Iyengar, R. Arthur, J.E. Manson et al. Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: a secondary analysis of a randomized clinical trial and observational study. JAMA Oncol. 5(2), 155–163 (2019). https://doi.org/10.1001/jamaoncol.2018.5327

44.

R.S. Cecchini, J.P. Costantino, J.A. Cauley et al. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev. Res 5(4), 583–592 (2012). https://doi.org/10.1158/1940-6207.CAPR-11-0482CrossRef

45.

M. Kawai, K.E. Malone, M.-T.C. Tang, C.I. Li, Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Cancer 120(10), 1548–1556 (2014). https://doi.org/10.1002/CNCR.28601CrossRefPubMed

46.

S. Sahin, G.U. Erdem, F. Karatas et al. The association between body mass index and immunohistochemical subtypes in breast cancer. Breast 32, 227–236 (2017). https://doi.org/10.1016/J.BREAST.2016.09.019CrossRefPubMed

47.

M. KB, T. KL, W. WC, Longitudinal study on the role of body size in premenopausal breast cancer. Arch. Intern. Med. 166(21), 2395–2402 (2006). https://doi.org/10.1001/ARCHINTE.166.21.2395CrossRef

48.

F. RT, E. AH, S. D, W. WC, B. RL, H. SE, Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses’ Health Study II. Breast Cancer Res. 15, (2013). https://doi.org/10.1186/BCR3394

49.

K. R, T. K, S. D et al. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—results from the EPIC cohort. Int. J. Cancer 134(8), 1947–1957 (2014). https://doi.org/10.1002/IJC.28528CrossRef

50.

B. Trabert, M.E. Sherman, N. Kannan, F.Z. Stanczyk, Progesterone and Breast Cancer. Endocr. Rev. 41(2), 320 (2020). https://doi.org/10.1210/ENDREV/BNZ001CrossRef

51.

S. BM, K. SG, Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J. Clin. Endocrinol. Metab. 39(1), 145–149 (1974). https://doi.org/10.1210/JCEM-39-1-145CrossRef

52.

K. TJ, P. MC, The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur. J. Cancer Clin. Oncol. 24(1), 29–43 (1988). https://doi.org/10.1016/0277-5379(88)90173-3CrossRef

53.

M. Dowsett, E. Folkerd, Reduced progesterone levels explain the reduced risk of breast cancer in obese premenopausal women: a new hypothesis. Breast Cancer Res. Treat. 149(1) (2015). https://doi.org/10.1007/S10549-014-3211-4

54.

B.A. Stoll, Impaired ovulation and breast cancer risk. Eur. J. Cancer 33(10), 1532–1535 (1997). https://doi.org/10.1016/S0959-8049(97)00117-2CrossRefPubMed

55.

M. JE, C. RT, S. ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13), 1353–1368 (2013). https://doi.org/10.1001/JAMA.2013.278040CrossRef

56.

R. Suzuki, N. Orsini, S. Saji, T.J. Key, A. Wolk, Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status—a meta-analysis. Int J. Cancer 124(3), 698–712 (2009). https://doi.org/10.1002/IJC.23943CrossRefPubMed

57.

S. Vingeliene, D.S.M. Chan, A.R. Vieira et al. An update of the WCRF/AICR systematic literature review and meta-analysis on dietary and anthropometric factors and esophageal cancer risk. Ann. Oncol. 28(10), 2409–2419 (2017). https://doi.org/10.1093/annonc/mdx338CrossRefPubMedPubMedCentral

58.

T. Psaltopoulou, T.N. Sergentanis, I. Ntanasis-Stathopoulos, I.G. Tzanninis, E. Riza, M.A. Dimopoulos, Anthropometric characteristics, physical activity and risk of hematological malignancies: a systematic review and meta-analysis of cohort studies. Int J. Cancer 145(2), 347–359 (2019). https://doi.org/10.1002/ijc.32109CrossRefPubMed

59.

T.N. Sergentanis, G. Tsivgoulis, C. Perlepe et al. Obesity and risk for brain/CNS tumors, gliomas and meningiomas: a meta-analysis. PLoS ONE. 10(9), (2015). https://doi.org/10.1371/journal.pone.0136974

60.

K. Bhaskaran, I. Douglas, H. Forbes, I. dos-Santos-Silva, D.A. Leon, L. Smeeth, Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet 384(9945), 755–765 (2014). https://doi.org/10.1016/S0140-6736(14)60892-8CrossRefPubMedPubMedCentral

61.

W.P. Koh, J.M. Yuan, R. Wang, H.P. Lee, M.C. Yu, Body mass index and smoking-related lung cancer risk in the Singapore Chinese Health Study. Br. J. Cancer 102(3), 610–614 (2010). https://doi.org/10.1038/sj.bjc.6605496CrossRefPubMed

62.

G.C. Chen, S.J. Chen, R. Zhang et al. Central obesity and risks of pre- and postmenopausal breast cancer: a dose–response meta-analysis of prospective studies. Obes. Rev. 17(11), 1167–1177 (2016). https://doi.org/10.1111/obr.12443CrossRefPubMed

63.

S.C. Houghton, H. Eliassen, R.M. Tamimi, W.C. Willett, B.A. Rosner, S.E. Hankinson, Central adiposity and subsequent risk of breast cancer by menopause status. JNCI J Natl Cancer Inst. (2020). https://doi.org/10.1093/jnci/djaa197

64.

A.J. White, H.B. Nichols, P.T. Bradshaw, D.P. Sandler, Overall and central adiposity and breast cancer risk in the Sister Study. Cancer 121(20), 3700–3708 (2015). https://doi.org/10.1002/cncr.29552CrossRefPubMed

65.

Y. Dong, J. Zhou, Y. Zhu et al. Abdominal obesity and colorectal cancer risk: Systematic review and meta-analysis of prospective studies. Biosci. Rep. 37(6), 20170945 (2017). https://doi.org/10.1042/BSR20170945CrossRef

66.

X. Du, K. Hidayat, B.M. Shi, Abdominal obesity and gastroesophageal cancer risk: Systematic review and meta-analysis of prospective studies. Biosci Rep. 37(3), (2017). https://doi.org/10.1042/BSR20160474

67.

L.L. Moore, M.L. Bradlee, M.R. Singer et al. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int. J. Obes. 28(4), 559–567 (2004). https://doi.org/10.1038/sj.ijo.0802606CrossRef

68.

World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project ExpertReport 2018. Body fatness and weight gain and the risk of cancer. https://www.wcrf.org/dietandcancer/exposures/body-fatness. Accessed 12 Jan 2021

69.

Obesity and cancer | Cancer World Archive. (2019) https://archive.cancerworld.net/e-grandround/obesity-and-cancer/. Accessed 2021

70.

J. Harding, M. Sooriyakumaran, K.J. Anstey et al. The metabolic syndrome and cancer: Is the metabolic syndrome useful forpredicting cancer risk above and beyond its individual components? Diabetes Metab. 41(6), 463–469 (2015). https://doi.org/10.1016/j.diabet.2015.04.006CrossRefPubMed

71.

T. Deng, C.J. Lyon, S. Bergin, M.A. Caligiuri, W.A. Hsueh, Obesity, inflammation, and cancer. Annu. Rev. Pathol. Mech. Dis. 11(1), 421–449 (2016). https://doi.org/10.1146/annurev-pathol-012615-044359CrossRef

72.

K.I. Avgerinos, N. Spyrou, C.S. Mantzoros, M. Dalamaga, Obesity and cancer risk: emerging biological mechanisms and perspectives. Metabolism 92, 121–135 (2019). https://doi.org/10.1016/j.metabol.2018.11.001CrossRefPubMed

73.

G. De Pergola, F. Silvestris, Obesity as a major risk factor for cancer. J. Obes. 2013 (2013). https://doi.org/10.1155/2013/291546

74.

M.G. Battelli, M. Bortolotti, L. Polito, A. Bolognesi, Metabolic syndrome and cancer risk: the role of xanthine oxidoreductase. Redox Biol. 21, (2019). https://doi.org/10.1016/j.redox.2018.101070

75.

F.M. Mendonça, F.R. De Sousa, A.L. Barbosa et al. Metabolic syndrome and risk of cancer: Which link? Metabolism 64(2), 182–189 (2015). https://doi.org/10.1016/j.metabol.2014.10.008CrossRefPubMed

76.

G. Pearson, F. Robinson, T. Beers Gibson et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev. 22(2), 153–183 (2001). https://doi.org/10.1210/edrv.22.2.0428CrossRefPubMed

77.

B. Cheatham, C.R. Kahn, Insulin action and the insulin signaling network. Endocr. Rev. 16(2), 117–142 (1995). https://doi.org/10.1210/edrv-16-2-117CrossRefPubMed

78.

M. Dalamaga, K.N. Diakopoulos, C.S. Mantzoros, The role of adiponectin in cancer: a review of current evidence. Endocr. Rev. 33(4), 547–594 (2012). https://doi.org/10.1210/er.2011-1015CrossRefPubMedPubMedCentral

79.

J.P. Després, I. Lemieux, Abdominal obesity and metabolic syndrome. Nature 444(7121), 881–887 (2006). https://doi.org/10.1038/nature05488CrossRefPubMed

80.

S. Brauna, K. Bitton-Worms, D. le Roith, The link between the metabolic syndrome and cancer. Int J. Biol. Sci. 7(7), 1003–1015 (2011). https://doi.org/10.7150/ijbs.7.1003CrossRef

81.

R. Jinjuvadia, P. Lohia, C. Jinjuvadia, S. Montoya, S. Liangpunsakul, The association between metabolic syndrome and colorectal neoplasm: Systemic review and meta-analysis. J. Clin. Gastroenterol. 47(1), 33–44 (2013). https://doi.org/10.1097/MCG.0b013e3182688c15CrossRefPubMedPubMedCentral

82.

K. Esposito, P. Chiodini, A. Capuano et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 44(3), 634–647 (2012). https://doi.org/10.1007/s12020-013-9939-5CrossRef

83.

B. Xia, Q. He, Y. Pan et al. Metabolic syndrome and risk of pancreatic cancer: a population-based prospective cohort study. Int J. Cancer 147(12), 3384–3393 (2020). https://doi.org/10.1002/ijc.33172CrossRefPubMed

84.

S.K. Park, C.M. Oh, M.H. Kim, E. Ha, Y.S. Choi, J.H. Ryoo, Metabolic syndrome, metabolic components, and their relation to the risk of pancreatic cancer. Cancer 126(9), 1979–1986 (2020). https://doi.org/10.1002/cncr.32737CrossRefPubMed

85.

R. Jinjuvadia, S. Patel, S. Liangpunsakul, The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J. Clin. Gastroenterol. 48(2), 172–177 (2014). https://doi.org/10.1097/MCG.0b013e3182a030c4CrossRefPubMed

86.

Y. Li, J. Shi, X. Liu, Q. Deng, Y. Huang, Z. Yang, Metabolic syndrome relates to high risk in hepatocellular carcinoma: a meta-analysis. Disco. Med. 26(144), 185–196 (2018). Accessed 11 Jan 2021

87.

H. Ren, J. Wang, Y. Gao, F. Yang, W. Huang, Metabolic syndrome and liver-related events: a systematic review and meta-analysis. BMC Endocr. Disord. 19(1), 40 (2019). https://doi.org/10.1186/s12902-019-0366-3CrossRefPubMedPubMedCentral

88.

E. Leoncini, G. Carioli, C. La Vecchia, S. Boccia, G. Rindi, Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann. Oncol. 27(1), 68–81 (2016). https://doi.org/10.1093/ANNONC/MDV505CrossRefPubMed

89.

S. AP, S. AC, C. C et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors. Cancers. 10(9), (2018). https://doi.org/10.3390/CANCERS10090293

90.

L. Barrea, G. Muscogiuri, R. Modica, Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front. Endocrinol. 12, 1 (2021). https://doi.org/10.3389/FENDO.2021.649496

91.

R. Bhandari, G.A. Kelley, T.A. Hartley, I.R.H. Rockett, Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int. J. Breast Cancer. 2014 (2014). https://doi.org/10.1155/2014/189384

92.

K. Esposito, P. Chiodini, A. Capuano et al. Metabolic syndrome and postmenopausal breast cancer: Systematic review and meta-analysis. Menopause 20(12), 1301–1309 (2013). https://doi.org/10.1097/GME.0b013e31828ce95dCrossRefPubMed

93.

M. Guo, T. Liu, P. Li et al. Association between metabolic syndrome and breast cancer risk: an updated meta-analysis of follow-up studies. Front Oncol. 9, (2019). https://doi.org/10.3389/fonc.2019.01290

94.

P. Zhao, N. Xia, H. Zhang, T. Deng, The metabolic syndrome is a risk factor for breast cancer: a systematic review and meta-analysis. Obes. Facts 13(4), 384–396 (2020). https://doi.org/10.1159/000507554CrossRefPubMedPubMedCentral

95.

L. Wang, Z.H. Du, J.M. Qiao, S. Gao, Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies. Aging 12(10), 9825–9839 (2020). https://doi.org/10.18632/aging.103247CrossRefPubMedPubMedCentral

96.

K. Esposito, P. Chiodini, A. Capuano, G. Bellastella, M.I. Maiorino, D. Giugliano, Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine 45(1), 28–36 (2014). https://doi.org/10.1007/s12020-013-9973-3CrossRefPubMed

97.

Y.Z. Xiang, H. Xiong, Z.L. Cui et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J. Exp. Clin. Cancer Res. 32(1), 9 (2013). https://doi.org/10.1186/1756-9966-32-9CrossRefPubMedPubMedCentral

98.

K. Esposito, P. Chiodini, A. Capuano et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J. Endocrinol. Investig. 36(2), 132–139 (2013). https://doi.org/10.1007/BF03346748CrossRef

99.

M. Gacci, C. De Nunzio, A. Sebastianelli et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 20(2), 146–155 (2017). https://doi.org/10.1038/pcan.2017.1CrossRefPubMed

100.

D.J. Crawley, L. Holmberg, J.C. Melvin et al. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer. 14(1), (2014). https://doi.org/10.1186/1471-2407-14-985

101.

H. Han, T. Zhang, Z. Jin et al. Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies. Oncotarget 8(30), 50164–50173 (2017). https://doi.org/10.18632/oncotarget.16816CrossRefPubMedPubMedCentral

102.

W.C. Liao, Y.K. Tu, M.S. Wu, J.T. Lin, H.P. Wang, K.L. Chien, Blood glucose concentration and risk of pancreatic cancer: Systematic review and dose-response meta-analysis. BMJ. 349, (2015). https://doi.org/10.1136/bmj.g7371

103.

Y. Huang, X. Cai, M. Qiu et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 57(11), 2261–2269 (2014). https://doi.org/10.1007/s00125-014-3361-2CrossRefPubMed

104.

K.K. Tsilidis, J.C. Kasimis, D.S. Lopez, E.E. Ntzani, J.P.A. Ioannidis, Type 2 diabetes and cancer: Umbrella review of meta-analyses of observationlal studies. BMJ. 350, (2015). https://doi.org/10.1136/bmj.g7607

105.

S. Ling, K. Brown, J.K. Miksza et al. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care 43(9), 2313–2322 (2020). https://doi.org/10.2337/dc20-0204CrossRefPubMed

106.

Cancer Prevention Recommendations | World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report. Recommendations and public health and policy implications. (2018) https://www.wcrf.org/dietandcancer/cancer-prevention-recommendations. Accessed 2021

107.

C.L. Rock, C. Thomson, T. Gansler, S.M. Gapstur, M.L. McCullough, A.V. Patel, K.S. Andrews, E.V. Bandera, C.K. Spees, K. Robien, S. Hartman, K. Sullivan, B.L. Grant, K.K. Hamilton, L.H. Kushi, B.J. Caan, D. Kibbe, J.D. Black, T.L. Wiedt, C. McMahon, K. Sloan, C. Doyle, American Cancer Society guideline for diet and physical activity for cancer prevention. CA A Cancer J Clinc, 70, 245–271 (2020). https://doi.org/10.3322/caac.21591

108.

L.N. Kohler, D.O. Garcia, R.B. Harris, E. Oren, D.J. Roe, E.T. Jacobs, Adherence to diet and physical activity cancer prevention guidelines and cancer outcomes: a systematic review. Cancer Epidemiol. Biomark. Prev. 25(7), 1018–1028 (2016). https://doi.org/10.1158/1055-9965.EPI-16-0121CrossRef

109.

H. Greenlee, G. Strizich, G.S. Lovasi et al. Concordance with prevention guidelines and subsequent cancer, cardiovascular disease, and mortality: a longitudinal study of older adults. Am. J. Epidemiol. 186(10), 1168–1179 (2017). https://doi.org/10.1093/aje/kwx150CrossRefPubMedPubMedCentral

110.

S.W. Andersen, W.J. Blot, X.O. Shu et al. Adherence to cancer prevention guidelines and cancer risk in low-income and african American populations. Cancer Epidemiol. Biomark. Prev. 25(5), 846–853 (2016). https://doi.org/10.1158/1055-9965.EPI-15-1186CrossRef

111.

G. Cifu, H. Arem, Adherence to lifestyle-related cancer prevention guidelines and breast cancer incidence and mortality. Ann. Epidemiol. 28(11), 767–773.e1 (2018). https://doi.org/10.1016/j.annepidem.2018.09.002CrossRefPubMed

112.

G. Onyeaghala, A.K. Lintelmann, C.E. Joshu et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention guidelines and colorectal cancer incidence among African Americans and whites: The Atherosclerosis Risk in Communities study. Cancer 126(5), 1041–1050 (2020). https://doi.org/10.1002/cncr.32616CrossRefPubMed

113.

Physical activity & cancer | World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report. Physical activity and the risk of cancer. Available at dietandcancerreport.org. (2018) https://www.wcrf.org/dietandcancer/exposures/physical-activity. Accessed 18 Jan 2021

114.

A.V. Patel, C.M. Friedenreich, S.C. Moore et al. American College of Sports Medicine roundtable report on physical activity, sedentary behavior, and cancer prevention and control. Med Sci. Sports Exerc. 51(11), 2391–2402 (2019). https://doi.org/10.1249/MSS.0000000000002117CrossRefPubMedPubMedCentral

115.

K.Y. Wolin, Y. Yan, G.A. Colditz, I.M. Lee, Physical activity and colon cancer prevention: a meta-analysis. Br. J. Cancer 100(4), 611–616 (2009). https://doi.org/10.1038/sj.bjc.6604917CrossRefPubMedPubMedCentral

116.

P.J. Hardefeldt, R. Penninkilampi, S. Edirimanne, G.D. Eslick, Physical activity and weight loss reduce the risk of breast cancer: a meta-analysis of 139 prospective and retrospective studies. Clin. Breast Cancer 18(4), e601–e612 (2018). https://doi.org/10.1016/j.clbc.2017.10.010CrossRefPubMed

117.

G. Behrens, M.F. Leitzmann, The association between physical activity and renal cancer: systematic review and meta-analysis. Br. J. Cancer 108(4), 798–811 (2013). https://doi.org/10.1038/bjc.2013.37CrossRefPubMedPubMedCentral

118.

D. Schmid, G. Behrens, M. Keimling, C. Jochem, C. Ricci, M. Leitzmann, A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur. J. Epidemiol. 30(5), 397–412 (2015). https://doi.org/10.1007/s10654-015-0017-6CrossRefPubMed

119.

M. Keimling, G. Behrens, D. Schmid, C. Jochem, M.F. Leitzmann, The association between physical activity and bladder cancer: Systematic review and meta-analysis. Br. J. Cancer 110(7), 1862–1870 (2014). https://doi.org/10.1038/bjc.2014.77CrossRefPubMedPubMedCentral

120.

G. Behrens, C. Jochem, M. Keimling, C. Ricci, D. Schmid, M.F. Leitzmann, The association between physical activity and gastroesophageal cancer: systematic review and meta-analysis. Eur. J. Epidemiol. 29(3), 151–170 (2014). https://doi.org/10.1007/s10654-014-9895-2CrossRefPubMed

121.

D.R. Brenner, D.H. Yannitsos, M.S. Farris, M. Johansson, C.M. Friedenreich, Leisure-time physical activity and lung cancer risk: a systematic review and meta-analysis. Lung Cancer 95, 17–27 (2016). https://doi.org/10.1016/j.lungcan.2016.01.021CrossRefPubMed

122.

G. Behrens, C.E. Matthews, S.C. Moore et al. The association between frequency of vigorous physical activity and hepatobiliary cancers in the NIH-AARP Diet and Health Study. Eur. J. Epidemiol. 28(1), 55–66 (2013). https://doi.org/10.1007/s10654-013-9767-1CrossRefPubMedPubMedCentral

123.

L.F.M. Rezende, T.H. de, Sá, G. de, Markozannes et al. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br. J. Sports Med. 52(13), 826–833 (2018). https://doi.org/10.1136/bjsports-2017-098391CrossRefPubMed

124.

S.C. Moore, I.M. Lee, E. Weiderpass et al. Association of leisure-time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176(6), 816–825 (2016). https://doi.org/10.1001/jamainternmed.2016.1548CrossRefPubMedPubMedCentral

125.

S. Birks, A. Peeters, K. Backholer, P. O’Brien, W. Brown, A systematic review of the impact of weight loss on cancer incidence and mortality. Obes. Rev. 13(10), 868–891 (2012). https://doi.org/10.1111/j.1467-789X.2012.01010.xCrossRefPubMed

126.

J. Luo, M. Hendryx, J.A.E. Manson et al. Intentional weight loss and obesity-related cancer risk. JNCI Cancer Spectr. 3(4) (2019). https://doi.org/10.1093/jncics/pkz054

127.

R.T. Chlebowski, J. Luo, G.L. Anderson et al. Weight loss and breast cancer incidence in postmenopausal women. Cancer 125(2), 205–212 (2019). https://doi.org/10.1002/cncr.31687CrossRefPubMed

128.

J. Luo, R.T. Chlebowski, M. Hendryx et al. Intentional weight loss and endometrial cancer risk. J. Clin. Oncol. 35(11), 1189–1193 (2017). https://doi.org/10.1200/JCO.2016.70.5822CrossRefPubMedPubMedCentral

129.

X. Zhang, J. Rhoades, B.J. Caan et al. Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis. Int J. Gynecol. Cancer 29(9), 1361–1371 (2019). https://doi.org/10.1136/ijgc-2019-000728CrossRefPubMedPubMedCentral

130.

Y.L. Feng, L. Shu, P.F. Zheng et al. Dietary patterns and colorectal cancer risk: a meta-analysis. Eur. J. Cancer Prev. 26(3), 201–211 (2017). https://doi.org/10.1097/CEJ.0000000000000245CrossRefPubMed

131.

J. Petimar, S.A. Smith-Warner, T.T. Fung et al. Recommendation-based dietary indexes and risk of colorectal cancer in the Nurses’ Health Study and Health Professionals Follow-up Study. Am. J. Clin. Nutr. 108(5), 1092–1103 (2018). https://doi.org/10.1093/ajcn/nqy171CrossRefPubMedPubMedCentral

132.

T. Fernández-Villa, L. Álvarez-Álvarez, M. Rubín-García, M. Obón-Santacana, V. Moreno, The role of dietary patterns in colorectal cancer: a 2019 update. Expert Rev. Gastroenterol. Hepatol. 14(4), 281–290 (2020). https://doi.org/10.1080/17474124.2020.1736043CrossRefPubMed

133.

F.K. Tabung, L.S. Brown, T.T. Fung, Dietary patterns and colorectal cancer risk: a review of 17 years of evidence (2000–2016). Curr. Colorectal Cancer Rep. 13(6), 440–454 (2017). https://doi.org/10.1007/s11888-017-0390-5CrossRefPubMedPubMedCentral

134.

H.F. Wang, A.L. Yao, Y.Y. Sun, A.H. Zhang, Empirically derived dietary patterns and ovarian cancer risk: a meta-analysis. Eur. J. Cancer Prev. 27(5), 493–501 (2018). https://doi.org/10.1097/CEJ.0000000000000367CrossRefPubMed

135.

P.Y. Lu, L. Shu, S.S. Shen, X.J. Chen, X.Y. Zhang, Dietary patterns and pancreatic cancer risk: a meta-analysis. Nutrients. 9(1) (2017). https://doi.org/10.3390/nu9010038

136.

Y. Xiao, J. Xia, L. Li et al. Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies. Breast Cancer Res. 21(1) (2019). https://doi.org/10.1186/s13058-019-1096-1

137.

C.J. Si, L. Shu, P.F. Zheng et al. Dietary patterns and endometrial cancer: a meta-analysis. Eur. J. Cancer Prev. 26(4), 336–345 (2017). https://doi.org/10.1097/CEJ.0000000000000266CrossRefPubMed

138.

C. Davis, J. Bryan, J. Hodgson, K. Murphy, Definition of the Mediterranean diet: a literature review. Nutrients 7(11), 9139 (2015). https://doi.org/10.3390/NU7115459CrossRefPubMedPubMedCentral

139.

L. Schwingshackl, C. Schwedhelm, C. Galbete, G. Hoffmann, Adherence to mediterranean diet and risk of cancer: An updated systematic review and meta-analysis. Nutrients. 9(10) (2017). https://doi.org/10.3390/nu9101063

140.

J. Morze, A. Danielewicz, K. Przybyłowicz, H. Zeng, G. Hoffmann, L.Schwingshackl, An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer. Eur. J. Nutr. (2020). https://doi.org/10.1007/s00394-020-02346-6

141.

S. Ahmad, O.V. Demler, Q. Sun et al. Association of the Mediterranean diet with onset of diabetes in the women’s health study. JAMA Netw. Open 3(11), e2025466 (2020). https://doi.org/10.1001/jamanetworkopen.2020.25466CrossRefPubMedPubMedCentral

142.

B.L, A.B, M.G et al. Impact of nutritional status on gastroenteropancreatic neuroendocrine tumors (GEP-NET) aggressiveness. Nutrients. 10(12) (2018). https://doi.org/10.3390/NU10121854

143.

L.D, B.L, M.G, A.G, C.A, S.S, Breast cancer prevention in premenopausal women: role of the Mediterranean diet and its components. Nutr. Res. Rev. 33(1), 19–32 (2020). https://doi.org/10.1017/S0954422419000167CrossRef

144.

D.Z, R.S, A new score for quantifying adherence to a cancer-preventive Mediterranean diet. Nutr. Cancer. (2021). https://doi.org/10.1080/01635581.2021.1909738

145.

S.E. Steck, E.A. Murphy, Dietary patterns and cancer risk. Nat. Rev. Cancer 20(2), 125–138 (2020). https://doi.org/10.1038/s41568-019-0227-4CrossRefPubMed

146.

D.R. Morales, A.D. Morris, Metformin in cancer treatment and prevention. Annu Rev. Med. 66, 17–29 (2015). https://doi.org/10.1146/annurev-med-062613-093128CrossRefPubMed

147.

R. Mallik, T.A. Chowdhury, Metformin in cancer. Diabetes Res Clin. Pr. 143, 409–419 (2018). https://doi.org/10.1016/j.diabres.2018.05.023CrossRef

148.

K. Zhang, P. Bai, H. Dai, Z. Deng, Metformin and risk of cancer among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Prim. Care Diabetes 15(1), 52–58 (2021). https://doi.org/10.1016/j.pcd.2020.06.001CrossRefPubMed

149.

C. Coyle, F.H. Cafferty, C. Vale, R.E. Langley, Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 27(12), 2184–2195 (2016). https://doi.org/10.1093/annonc/mdw410CrossRefPubMedPubMedCentral

150.

C.A.W. Ng, A.A. Jiang, E.M.S. Toh et al. Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. Int J. Colorectal Dis. 35(8), 1501–1512 (2020). https://doi.org/10.1007/s00384-020-03676-xCrossRefPubMed

151.

S. Zaidi, J. Gandhi, G. Joshi, N.L. Smith, S.A. Khan, The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis. 22(3), 351–361 (2019). https://doi.org/10.1038/s41391-018-0085-2CrossRefPubMed

152.

C. Cao, S. Yang, Z. Zhou, GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66(2), 157–165 (2019). https://doi.org/10.1007/s12020-019-02055-zCrossRefPubMed

153.

G.F. Piccoli, L.A. Mesquita, C. Stein et al. Do GLP-1 receptor agonists increase the risk of breast cancer? A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. (2020). https://doi.org/10.1210/clinem/dgaa891

154.

I.N. Colmers, S.L. Bowker, J.A. Johnson, Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 38(6), 475–484 (2012). https://doi.org/10.1016/j.diabet.2012.06.003CrossRefPubMed

155.

C. Bosetti, V. Rosato, D. Buniato, A. Zambon, C. La Vecchia, G. Corrao, Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta‐analysis. Oncologist 18(2), 148–156 (2013). https://doi.org/10.1634/theoncologist.2012-0302CrossRefPubMedPubMedCentral

156.

S. He, Y.H. Tang, G. Zhao, X. Yang, D. Wang, Y. Zhang, Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis. Tumor Biol. 35(3), 2095–2102 (2014). https://doi.org/10.1007/s13277-013-1278-xCrossRef

157.

M. Ferwana, B. Firwana, R. Hasan et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet. Med. 30(9), 1026–1032 (2013). https://doi.org/10.1111/dme.12144CrossRefPubMed

158.

H. Tang, W. Shi, S. Fu et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 7(4), 1070–1080 (2018). https://doi.org/10.1002/cam4.1354CrossRefPubMedPubMedCentral

159.

Y. Chen, L. Liu, Q. Zhou et al. Body mass index had different effects on premenopausal and postmenopausal breast cancer risks: a dose-response meta-analysis with 3,318,796 subjects from 31 cohort studies. BMC Public Health 17(1), 936 (2017). https://doi.org/10.1186/s12889-017-4953-9CrossRefPubMedPubMedCentral

Titel: Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations
verfasst von: Nikoletta Mili
Stavroula A. Paschou
Dimitrios G. Goulis
Meletios-Athanasios Dimopoulos
Irene Lambrinoudaki
Theodora Psaltopoulou
Publikationsdatum: 08.10.2021
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2021
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-021-02884-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials

Association of decreased sperm motility and increased seminal plasma IGF-I, IGF-II, IGFBP-2, and PSA levels in infertile men

Correlation between inflammatory parameters and pituitary–thyroid axis in patients with COVID-19

Bone and body composition analyses by DXA in adults with GH deficiency: effects of long-term replacement therapy

Postoperatively determined high-risk histopathologic features in papillary thyroid carcinoma initially eligible for thyroid lobectomy: a game changer

Letter to “Levothyroxine absorption test results in patients with TSH elevation resistant to treatment”

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin